Five Presentations Will Highlight Findings from the XIPERE® Pivotal Phase 3 Program VAUGHAN, ON, July 6, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global …
Tag:
(triamcinolone
-
-
“XIPERE® is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients who struggle with macular edema associated with uveitis, which is …